Immunoengineering via Chimeric Antigen Receptor-T Cell Therapy: Reprogramming Nanodrug Delivery

• Váldodahkkit: Theodora Katopodi (Dahkki), Savvas Petanidis (Dahkki), Doxakis Anestakis (Dahkki), Charalampos Charalampidis (Dahkki), Ioanna Chatziprodromidou (Dahkki), George Floros (Dahkki), Panagiotis Eskitzis (Dahkki), Paul Zarogoulidis (Dahkki), Charilaos Koulouris (Dahkki), Christina Sevva (Dahkki), Konstantinos Papadopoulos (Dahkki), Marios Dagher (Dahkki), Nikolaos Varsamis (Dahkki), Vasiliki Theodorou (Dahkki), Chrysi Maria Mystakidou (Dahkki), Nikolaos Iason Katsios (Dahkki), Konstantinos Farmakis (Dahkki), Christoforos Kosmidis (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: MDPI AG, 2023-10-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Following its therapeutic effect in hematological metastasis, chimeric antigen receptor (CAR) T cell therapy has gained a great deal of attention during the last years. However, the effectiveness of this treatment has been hampered by a number of challenges, including significant toxicities, difficu...